SEC Comment Letter 0000000000-23-000427 to Gracell Biotechnologies Inc. (CIK 0001826492)
Gracell Biotechnologies Inc. (CIK 0001826492)
Date: Jan. 17, 2023 · CIK: 0001826492 · Accession: 0000000000-23-000427
AI Filing Summary & Sentiment
File numbers found in text: 001-39838
Letter
United States securities and exchange commission logo January 17, 2023 Yili Kevin Xie Chief Financial Officer Gracell Biotechnologies Inc. Building 12, Block B, Phase II Biobay Industrial Park 218 Sangtian St. Suzhou Industrial Park, 215123 People’s Republic of China Re:Gracell Biotechnologies Inc. Form 20-F for Fiscal Year Ended December 31, 2021 Filed April 22, 2022 File No. 001-39838 Dear Yili Kevin Xie: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 17, 2023
Yili Kevin Xie
Chief Financial Officer
Gracell Biotechnologies Inc.
Building 12, Block B, Phase II
Biobay Industrial Park
218 Sangtian St.
Suzhou Industrial Park, 215123
People’s Republic of China
Re:Gracell Biotechnologies Inc.
Form 20-F for Fiscal Year Ended December 31, 2021
Filed April 22, 2022
File No. 001-39838
Dear Yili Kevin Xie:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences